Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease

Treatment of pulmonary infection requires long-term administration of multiple antibiotics. Little is known, however, about the impact of each antibiotic on treatment outcomes. A retrospective analysis was conducted to evaluate the efficacy and adverse effects of antibiotics administered in 244 case...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 10; p. 1977
Main Authors Chen, Jianhui, Zhao, Lan, Mao, Yanhua, Ye, Meiping, Guo, Qi, Zhang, Yongjie, Xu, Liyun, Zhang, Zhemin, Li, Bing, Chu, Haiqing
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.08.2019
Subjects
adverse effect
drug
efficacy
Microbiology
Mycobacterium abscessus
pulmonary disease
adverse effect
pulmonary disease
Mycobacterium abscessus
efficacy
drug
Online AccessGet full text

Cover

More Information
Summary:Treatment of pulmonary infection requires long-term administration of multiple antibiotics. Little is known, however, about the impact of each antibiotic on treatment outcomes. A retrospective analysis was conducted to evaluate the efficacy and adverse effects of antibiotics administered in 244 cases of pulmonary disease. Only 110 (45.1%) patients met the criteria for treatment success. The efficacy of treating pulmonary disease continues to be unsatisfactory especially for infections involving subsp. . Treatment with drug combinations that included amikacin [adjusted odds ratio (AOR), 3.275; 95% confidence interval (CI), 1.221-8.788], imipenem (AOR, 2.078; 95% CI, 1.151-3.753), linezolid (AOR, 2.231; 95% CI, 1.078-4.616), or tigecycline (AOR, 2.040; 95% CI, 1.079-3.857) was successful. Adverse side effects affected the majority of patients (192/244, 78.7%). Severe effects that resulted in treatment modification included: gastrointestinal distress (29/60, 48.3%) mostly caused by tigecycline, ototoxicity (14/60, 23.3%) caused by amikacin; and myelosuppression (6/60, 10%) caused mainly by linezolid. In conclusion, the success rate of treatment of pulmonary disease is still unsatisfactory. The administration of amikacin, imipenem, linezolid, and tigecycline correlated with increased treatment success. Adverse side effects are common due to long-term, combination antibiotic therapy. Ototoxicity, gastrointestinal distress, and myelosuppression are the most severe.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Jesica Mazza-Stalder, Lausanne University Hospital (CHUV), Switzerland
Reviewed by: Oriol Manuel, Lausanne University Hospital (CHUV), Switzerland; Amit Kaushik, Johns Hopkins University, United States
These authors have contributed equally to this work
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2019.01977